Article ID Journal Published Year Pages File Type
2487639 Journal of Pharmaceutical Sciences 2007 13 Pages PDF
Abstract
Progesterone has been known to be polymorphic for over 70 years, and crystallization conditions for the production of both experimentally characterized polymorphs have been repeatedly reported in the literature up to 1975. Nevertheless, our attempts to produce crystals of the metastable form 2 suitable for single crystal X‐ray diffraction failed until the structurally related molecule pregnenolone was introduced as an additive into the crystallization solution. Accurate low temperature crystal structures were obtained for forms 1 and 2, pregnenolone and a newly discovered pregnenolone-progesterone co‐crystal, which appeared concomitantly with progesterone forms 1 and 2. Computational work based on the experimental crystal structures and those generated by a search for low energy structures showed that the crystallization of enantiomerically pure progesterone results in a more strained conformation compared with the racemate due to the rotation of the acetyl and 21‐methyl groups. The role of impurities or additives in influencing crystallization outcome is discussed. © 2007 Wiley‐Liss, Inc. and the American Pharmacists Association J Pharm Sci 96: 3419-3431, 2007
Related Topics
Health Sciences Pharmacology, Toxicology and Pharmaceutical Science Drug Discovery
Authors
, , , , , ,